Human keratin 8 variants promote mouse acetaminophen hepatotoxicity coupled with c‐jun amino‐terminal kinase activation and protein adduct formation

Nurdan Guldiken, Qin Zhou, Ozlem Kucukoglu, Melanie Rehm, Kateryna Levada, Annika Gross, Raymond Kwan, Laura P. James, Christian Trautwein, M. Bishr Omary, Pavel Strnad – 11 May 2015 – Keratins 8 and 18 (K8/K18) are the intermediate filaments proteins of simple‐type digestive epithelia and provide important cytoprotective function. K8/K18 variants predispose humans to chronic liver disease progression and poor outcomes in acute acetaminophen (APAP)‐related liver failure.

Hepatocellular carcinoma risk in chronic hepatitis B virus–infected compensated cirrhosis patients with low viral load

Dong Hyun Sinn, Junggyu Lee, Juna Goo, Kyunga Kim, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Byung Chul Yoo, Seung Woon Paik – 11 May 2015 – Controversy exists about whether antiviral therapy (AVT) should be recommended for compensated cirrhosis patients with chronic hepatitis B virus (HBV) infection and detectable, but low, serum HBV‐DNA levels.

Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1

Sheng‐xian Yuan, Jie Wang, Fu Yang, Qi‐fei Tao, Jin Zhang, Li‐li Wang, Yuan Yang, Hui Liu, Zhen‐guang Wang, Qing‐guo Xu, Jia Fan, Lei Liu, Shu‐han Sun, Wei‐ping Zhou – 11 May 2015 – Tumor cells with stemness (stem‐cell) features contribute to initiation and progression of hepatocellular carcinoma (HCC), but involvement of long noncoding RNAs (lncRNAs) remains largely unclear. Genome‐wide analyses were applied to identify tumor‐associated lncRNA‐DANCR. DANCR expression level and prognostic values of DANCR were assayed in two HCC cohorts (China and Korea, n = 135 and 223).

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials

Saleh A. Alqahtani, Nezam Afdhal, Stefan Zeuzem, Stuart C. Gordon, Alessandra Mangia, Paul Kwo, Michael Fried, Jenny C. Yang, Xiao Ding, Phillip S. Pang, John G. McHutchison, David Pound, K. Rajender Reddy, Patrick Marcellin, Kris V.

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials

Saleh A. Alqahtani, Nezam Afdhal, Stefan Zeuzem, Stuart C. Gordon, Alessandra Mangia, Paul Kwo, Michael Fried, Jenny C. Yang, Xiao Ding, Phillip S. Pang, John G. McHutchison, David Pound, K. Rajender Reddy, Patrick Marcellin, Kris V.

Hepatocellular carcinoma risk in chronic hepatitis B virus–infected compensated cirrhosis patients with low viral load

Dong Hyun Sinn, Junggyu Lee, Juna Goo, Kyunga Kim, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Byung Chul Yoo, Seung Woon Paik – 11 May 2015 – Controversy exists about whether antiviral therapy (AVT) should be recommended for compensated cirrhosis patients with chronic hepatitis B virus (HBV) infection and detectable, but low, serum HBV‐DNA levels.

Metastasis‐associated in colon cancer 1 is an independent prognostic biomarker for survival in klatskin tumor patients

Andri Lederer, Pia Herrmann, Daniel Seehofer, Manfred Dietel, Johann Pratschke, Peter Schlag, Ulrike Stein – 8 May 2015 – Curative treatment of intrahepatic cholangiocarcinoma (ICC) and hilar cholangiocarcinoma (Klatskin tumors) is limited to surgical resection or orthotopic liver transplantation. However, not all patients benefit from a surgical approach and suffer from early tumor recurrence. Response to chemotherapy is generally poor and, until today, no targeted therapy could be established.

Identification of microRNAs specific for epithelial cell adhesion molecule–positive tumor cells in hepatocellular carcinoma

Junfang Ji, Xin Zheng, Marshonna Forgues, Taro Yamashita, Eliane L. Wauthier, Lola M. Reid, Xinyu Wen, Young Song, Jun S. Wei, Javed Khan, Snorri S. Thorgeirsson, Xin Wei Wang – 8 May 2015 – Therapies that target cancer stem cells (CSCs) hold promise in eliminating cancer burden. However, normal stem cells are likely to be targeted owing to their similarities to CSCs. It is established that epithelial cell adhesion molecule (EpCAM) is a biomarker for normal hepatic stem cells (HpSCs), and EpCAM+AFP+ hepatocellular carcinoma (HCC) cells have enriched hepatic CSCs.

Subscribe to